Chromogen to cooperate with government investigation

May 18, 2015

Chromogen of Walnut Creek, California, one of the world’s leading biogenetic companies, today confirmed that a government investigation into its laboratory practices has indeed been initiated. Chromogren CEO Desmond Wright, has issued a statement:

“Chromogen plans to cooperate fully with the agencies involved. Furthermore the company is confident that once the investigation is complete, the result will establish that Chromogen has rigorously adhered to all requirements of federal law, and in fact applies in more stringent controls on its research than the law currently demands.”

Chromogen delaying its highly-anticipated public offering

April 12, 2014

Chromogen, the privately-held biogenetics company in Walnut Creek, California, announced it is delaying its highly-anticipated public offering.

Elliot Plevin, the wunderkind chief scientist of Chromogen, explained that its signature product, Everest 328, must undergo additional laboratory-controlled blind testing, before it can be submitted to the Federal Drug Administration for approval. Chromogen realizes that little is known about the drug. Chromogen will not respond directly to rumors beyond the following. As was stated previously the drug is intended to create a receptive biological environment for unprecedented genetic manipulation.

Chromogen announces breakthrough in genetic manipulation

January 25, 2012

The Chromogen Corporation, one of the leading biogenetic firms in Silicon Valley, today announced a breakthrough in genetic manipulation.

Until now, genetic research has been conducted in less than ideal conditions. While obviously proper laboratory checks and balances must be followed, Chromogen believes that an overly-conservative approach to maintaining the integrity of the environment wherein testing occurs is holding back significant advancement in the field.

Chromogen Corporation builds new facility

October 7, 2010

Privately-held Chromogen Corporation builds new one hundred million dollar facility in Walnut Creek, California.

The bio-genetics firm, launched two years ago, has already patented over thirty ground-breaking procedures for gene study and manipulation. CEO Desmond Wright says, “the company hopes these techniques will pave the way for a series of industry-leading products to enhance human life.”